DaVita Inc. (DVA): Price and Financial Metrics

DaVita Inc. (DVA): $94.28

-0.78 (-0.82%)

POWR Rating

Component Grades













DVA Price/Volume Stats

Current price $94.28 52-week high $103.00
Prev. close $95.06 52-week low $65.28
Day low $93.73 Volume 413,900
Day high $95.41 Avg. volume 665,760
50-day MA $87.22 Dividend yield N/A
200-day MA $82.98 Market Cap 8.55B

DVA Stock Price Chart Interactive Chart >


  • Quality is the dimension where DVA ranks best; there it ranks ahead of 84.8% of US stocks.
  • The strongest trend for DVA is in Stability, which has been heading up over the past 179 days.
  • DVA ranks lowest in Momentum; there it ranks in the 4th percentile.

DVA Stock Summary

  • DAVITA INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 97.66% of US listed stocks.
  • For DVA, its debt to operating expenses ratio is greater than that reported by 83.23% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 25.31 for DAVITA INC; that's greater than it is for 98.4% of US stocks.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are IRM, CNK, THC, ENR, and SMG.
  • Visit DVA's SEC page to see the company's official filings. To visit the company's web site, go to www.davita.com.

DVA Valuation Summary

  • In comparison to the median Healthcare stock, DVA's price/sales ratio is 63.64% lower, now standing at 0.8.
  • Over the past 243 months, DVA's price/sales ratio has gone down 0.

Below are key valuation metrics over time for DVA.

Stock Date P/S P/B P/E EV/EBIT
DVA 2023-05-23 0.8 10.7 17.1 18.4
DVA 2023-05-22 0.8 11.0 17.6 18.6
DVA 2023-05-19 0.8 11.0 17.7 18.7
DVA 2023-05-18 0.8 11.1 17.8 18.7
DVA 2023-05-17 0.8 10.8 17.4 18.5
DVA 2023-05-16 0.8 10.8 17.4 18.5

DVA Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 18.38%.
  • The 5 year cash and equivalents growth rate now stands at 1.1%.
  • The 3 year revenue growth rate now stands at 2.81%.
Over the past 15 months, DVA's revenue has gone up $71,074,000.

The table below shows DVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 11,636.97 1,750.736 679.77
2022-06-30 11,626.6 1,607.156 834.158
2022-03-31 11,616.35 2,098.767 903.169
2021-12-31 11,618.8 1,930.876 978.45
2021-09-30 11,580.15 1,885.786 964.75
2021-06-30 11,565.9 1,801.561 863.67

DVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DVA has a Quality Grade of B, ranking ahead of 81.19% of graded US stocks.
  • DVA's asset turnover comes in at 0.661 -- ranking 45th of 81 Healthcare stocks.
  • LHCG, NTRA, and CHE are the stocks whose asset turnover ratios are most correlated with DVA.

The table below shows DVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.661 0.312 0.082
2021-06-30 0.666 0.314 0.078
2021-03-31 0.650 0.310 0.074
2020-12-31 0.651 0.308 0.077
2020-09-30 0.648 0.313 0.083
2020-06-30 0.643 0.310 0.082

DVA Price Target

For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.11 Average Broker Recommendation 2 (Hold)

DaVita Inc. (DVA) Company Bio

DaVita Inc. provides kidney dialysis services through a network of 2,816 outpatient dialysis centers in the United States, serving 204,200 patients, and 321 outpatient dialysis centers in 10 other countries serving 3,200 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. The company has a 37% market share in the U.S. dialysis market. It is organized in Delaware and based in Denver. (Source:Wikipedia)

DVA Latest News Stream

Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream

Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about DAVITA INC that investors may wish to consider to help them evaluate DVA as an investment opportunity.

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

Yahoo | May 22, 2023

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Yahoo | May 22, 2023

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Yahoo | May 22, 2023

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

Yahoo | May 19, 2023

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.

Yahoo | May 19, 2023

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 4.34%
3-mo 14.61%
6-mo 27.87%
1-year -3.58%
3-year 16.45%
5-year 37.92%
YTD 26.26%
2022 -34.36%
2021 -3.10%
2020 56.47%
2019 45.80%
2018 -28.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7777 seconds.